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1. Table in the JAMA Clinical Evidence Synopsis by Das and Singh (2014)
The JAMA Clinical Evidence Synopsis “Oral zinc for the common cold” by Das and Singh (2014) 
is based on the Cochrane review “Zinc for the common cold” by Singh and Das (2013).
The Cochrane review by Singh and Das (2013) is restricted to “double-blind, placebo-controlled 
randomised controlled trials” (p. 7, Singh and Das 2013). The JAMA Clinical Evidence Synopsis 
consistently states in the section “Evidence Profile” that the “No. of randomized clinical trials: 
14 therapeutic (lozenges: low-dose = 5, high-dose = 7; syrup = 2) among adults (13 trials) and 
children (1 trial) and 2 prophylactic trials among children only (syrup = 1, tablet = 1)” and these 
studies are included as “Comparison: Placebo” (p. 1440, Das and Singh 2014). This description 
implies that the findings presented in the JAMA Synopsis are also based on placebo-controlled 
randomized studies.
The main findings of the Cochrane review by Singh and Das (2013) are shown in a single Table 
in the JAMA Clinical Evidence Synopsis by Das and Singh (2014, p. 1441). The part of the Table 
that describes findings on the effect of zinc on the “duration of colds” is copied at the foot of this 
page, see below.
Most of the figures in this Table published in the JAMA Synopsis are not directly extracted 
from the Cochrane review by Singh and Das (2013) and the origin of the figures is not clear. 
The purpose of this document is to trace the origin of the figures in the Table, and to reproduce 
the calculations, in order to assess the validity of the reported findings in the Table in Das and Singh
(2014). 
 
 
 
 
 
The Table in the JAMA Synopsis by Das and Singh (2014, p. 1441)
 
 
 
 
3
2. Calculation of the difference in the effect between 
“High dose (≥75mg/d) vs low dose (<75mg/d) zinc lozenges”
 
On the third row of the Table (see p. 3), Das and Singh (2014) reported that in 5 studies 
with 543 participants, the means of the duration of colds were as follows: 
4.47 days (SD 0.52) in the high zinc dose groups, and 
8.68 days (SD 1.9) in the low zinc dose groups. 
In the Table, the difference in cold duration between the high vs low dose zinc lozenge groups 
was reported as: 
“−3.43 (−3.9 to −2.95)” days.
These findings are also repeated in the text section:
“The mean duration of the common cold was 4.47 days in high-dose users (≥75 mg/d) and 8.68 
days in low-dose users (<75 mg/d; mean difference, −3.43 [95% CI, −3.9 to −2.95])” (p. 1440).
 
It is not evident in the JAMA Synopsis, where the data for the “high dose vs low dose” comparison 
originated. The JAMA Synopsis is based on the Cochrane review by Singh and Das (2013), but 
that review does not include any comparison of 5 studies with 2 different dosage levels of zinc. 
Furthermore, so far only one publication has reported a randomized comparison between high 
and low zinc doses. The Turner (2000) study had 4 study arms: 1 arm was administered >75 mg/day
of zinc, 2 arms were administered <75 mg/day, and 1 arm was the placebo group. There are no other
studies with separate study arms that cover different doses of zinc. Thus, there does not appear 
to be 5 randomized studies that have compared high dose vs low dose of zinc as zinc lozenges.
I examined the Cochrane review by Singh and Das (2013) to ascertain where the data for the 
“high dose vs low dose zinc lozenges” comparison originates and whether the calculations leading 
to the reported values can be reproduced.
The above data reported in the JAMA Synopsis can be traced to Analysis 1.2 in the Cochrane 
review by Singh and Das (2013, p. 51). Subgroup 1.2.1 contains 7 high dose (>75 mg/day) zinc 
lozenge studies and subgroup 1.2.2 contains 5 low dose (<75 mg/day) zinc lozenge studies. In total, 
the zinc groups of these 12 studies had 668 (= 311 + 357) participants, see p. 6 of this document. 
In the Table published in the JAMA Synopsis, Das and Singh (2014) report that the number of 
participants in the 5 studies was 543 (see the Table on p. 3). The difference between the zinc 
lozenge groups published in Singh and Das (2013) and in Das and Singh (2014) is 125 participants 
(668 – 543 = 125). The same value appears as the sum of the 2 lowest listed high dose zinc lozenge 
groups (57 + 68); i.e. Smith (1989) and Turner (2000) in the subgroup 1.2.1 (high zinc), see p. 6. 
Thus, the zinc groups of the top 5 studies with high-dose zinc and all the 5 studies with low-dose 
zinc in Analysis 1.2 combined equal the number of participants that is reported on the third row 
of the Table of the JAMA Synopsis (i.e. N = 543).
Thereafter I examined whether the means and SDs reported in the JAMA synopsis could be 
reproduced from these 2 sets of 5 zinc groups, see pp. 6-7.
The unweighed mean duration of colds for the 5 high dose studies shown within the red rectangles 
on p. 6 is 4.47 days, and for the 5 low dose studies shown within red rectangles is 8.68 days, see 
the calculations on p. 7 of this document. Both of these figures are identical with the mean durations
of colds published in the JAMA Synopsis, compare them with the Table on p. 3.
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The standard deviations (SDs) calculated from the 5 means within the 2 rectangles are 0.52 days 
and 1.9 days, see p. 7. They are also identical with the SDs published in the JAMA Synopsis, 
compare them with the Table on p. 3.
Finally, the JAMA Synopsis reported that the difference between the high zinc dose and low zinc 
dose studies was −3.43 (95% CI: −3.9 to −2.95) days (see the Table on p. 3). This estimate and 
its 95% CI can be reproduced by including the 5 high dose and 5 low dose zinc groups as pairs 
in the same order as they were published in Analysis 1.2 of the Cochrane review by Singh and 
Das (2013), see p. 8 of this document for the forest plot. Compare the order of values under Mean, 
SD and Total on the right-hand side (“low zinc”) of the meta-analysis with the order of the 5 zinc 
groups in the low dose studies in Analysis 1.2.2, see p. 6 of this document.
Thus, Das and Singh (2014) do not give any explanations in the JAMA synopsis as to how they 
calculated the figures that they reported on the third row of their Table (p. 1441, Das and Singh 
2014). The figures do not originate directly or exclusively from their Cochrane review (Singh and 
Das 2013). Nevertheless, the origin of the figures for the “high dose vs low dose zinc lozenges” 
comparison can be traced and the calculations for the mean (SD) duration of colds and the estimate 
of effect and its 95% CI can be reproduced as shown above. 
It is highly unlikely that some other combination of the high dose and low dose zinc lozenge groups
would be consistent with the statement of “No. of studies: 5” and would lead to the same number 
of participants, the same mean (SD) values in low and high dose groups, and with the accuracy 
to two decimal places to the same estimate of difference and its 95% CI limits, as the selection 
and pairing of the zinc groups described above, and shown on pp. 7-8. Thus, the calculations 
on p. 7 and the meta-analysis on p. 8 seem to reproduce the analysis that is behind the figures 
that are reported on the third line of the Table in the JAMA Synopsis, see p. 3.
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Analysis 1.2 in the Cochrane review “zinc for the common cold” 
by Singh and Das (2013, p. 51).
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Calculation of the mean and SD from the means reported in Analysis 1.2 
of the Cochrane review “zinc for the common cold” by Singh and Das (2013)
 
Bold figures indicate the values that are reported in the JAMA Synopsis by Das and Singh (2014).
See the previous page for the copy of Analysis 1.2.
 
Reproducing the analysis of the difference between “high dose vs low dose zinc 
lozenges” in the JAMA synopsis by Das and Singh (2014)
 Analysis 1.2.1 by Singh and Das (2013)
 High dose (>75 mg/day) Study No. ofparticipants
Duration of colds
(days)
Godfrey (1992) 35 4.86
Mossad (1996) 49 5.2  
Petrus (1998) 52 3.8  
Prasad (2000) 25 4.5  
Prasad (2008) 25 4    
  Not included:  Smith (1989)
  Not included:  Turner (2000a)
Total  186  
Mean (unweighed)  4.47
SD (population)    0.521
 Analysis 1.2.2 of Singh and Das (2013)
 Low dose (<75 mg/day) Study
Douglas (1987) 33 12.1   
Macknin (1998) 123  9.37
Turner (2000b) 68 6.89
Turner (2000c) 72 7.9  
Weismann (1990) 61 7.16
Total  357  
Mean (unweighed)  8.68
SD (population)  1.91
Overall Total  543  
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Meta-analysis reproducing the reported mean difference and its 95% CI
in JAMA Synopsis by Das and Singh (2014)
 
 
 
 
The analysis above was done by Hemilä (2015) to reproduce the estimate of differences 
and its 95% CI on the third row in the Table of JAMA Synopsis (Das and Singh 2014), see p. 3. 
The RevMan program was used to calculate the pooled effect and construct the forest plot.
 
 
The meta-analysis above is based on the following pairs of zinc groups: 
 
 
The pairing in the above meta-analysis Some of the differences between the studies
 
“High zinc” – “Low zinc” “High zinc” –“Low zinc”
Godfrey 1992 – Douglas 1987 USA (18-40 y) - Australia (mean 33 y)
- lozenge composition, p 10
Mossad 1996 – Macknin 1998 Adults (21-69 y) - Children (6-16 y)
Petrus 1998 – Turner 2000b - lozenge composition, p 10
Prasad 2000 – Turner 2000c - lozenge composition, p 10
Prasad 2008 – Weismann 1990 USA (28-41 y) - Denmark (18-65 y)
The high zinc and low zinc groups above are in the same order as they appeared in Analysis 1.2 
of Singh and Das (2013), compare with p. 6 of this document.
The resulting estimate and its 95% CI are identical with that published in the JAMA Synopsis by 
Das and Singh (2014), compare with the Table on p. 3.
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The calculations for the comparison of “high dose vs low dose zinc lozenges” 
by Das and Singh (2014), described on the previous pages, have serious problems:
A) The JAMA Synopsis by Das and Singh (2014) gives a strong impression to the reader that all 
the described findings are based on randomized comparisons: “Evidence Profile ... randomized 
clinical trials” (Das and Singh 2014, p. 1440). However, the comparison of “high dose vs low dose”
groups by Das and Singh (2014) is not based on randomized groups, but it is instead based 
on different zinc groups from different studies with different conditions. There are numerous 
differences between the paired groups in addition to the zinc dosage, thus it is not reasonable 
to assume that the dose of zinc is the only difference between the paired high dose and low dose 
groups. Finally, the only published randomized comparison of different doses of zinc by Turner 
(2000) is missing from the pairings, see pp. 7-8, although Turner (2000a) is listed as a “high zinc 
dose” group in Analysis 1.2.1 by Singh and Das (2013), see p. 6.
B) Selection of the 5 high dose zinc studies for the comparisons is arbitrary and biased. Analysis 
1.2.1 includes 7 high dose zinc groups. Das and Singh (2014) selected 5 of them, leaving out 
the 2 high dose zinc groups with the longest durations of the cold, see p. 6. The mean duration 
of colds in these 2 excluded studies were: 7.23 days (Smith 1989) and 7.41 days (Turner 2000a), 
see p. 6. The cold durations reported in those 2 studies are 2 days longer than the third longest colds
of 5.2 days duration reported in the Mossad (1996) study. Thus, by excluding the Smith (1989) 
and the Turner (2000a) high dose zinc groups, Das and Singh (2014) bias the estimate of the 
duration of colds in the high dose zinc lozenge groups (i.e. the 4.47 days) towards shorter cold 
durations. The estimate of the difference between high dose and low dose groups is simultaneously 
skewed towards a greater value (i.e. the 3.43 days).
C) The estimated value of the difference between the high dose and low dose groups depends on 
the order of how the studies are paired in the meta-analysis. The reproduced comparison on p. 8 is 
based on taking the high zinc and the low zinc groups in the same order as they appear in Analyses 
1.2.1 and 1.2.2, compare pp. 6 and 8. These pairings resulted in the difference and its 95% CI 
published by Das and Singh (2014). However, there is no basis for considering that the high dose 
zinc group of Godfrey (1992) (USA) is most similar to the low dose zinc group of Douglas (1987) 
(Australia), or that the high dose zinc group of Mossad (1996) (Adults) is most similar to the low 
dose zinc group of Macknin (1998) (Children), etc, see p. 8. There is no justification for this 
particular arbitrary pairing of the 2 sets of 5 zinc groups.
D) When the number of participants varies between 25 and 49 in the high dose studies and between 
33 and 123 in the low dose studies (see pp. 6-7), it is not reasonable to pool the results by 
calculating an unweighed mean duration of the groups. When the overall means are calculated 
for the 2 sets of 5 zinc groups, the variation in the size of the groups should be taken into account 
by weighing the individual means.
E) Calculating the SD for the overall mean of the 5 zinc groups from the point estimates of 
the 5 groups is not the correct approach. The SD for the overall mean should be calculated from 
the SDs of the 5 groups, and not from the point estimates of the 5 groups (i.e. means).
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As stated in comments B) and C) above, the selection of 5 high dose zinc groups out of all 
the 7 high dose zinc groups is arbitrary, and their pairing with the low dose zinc groups is also 
arbitrary. If the high dose zinc groups with the shortest duration of colds by Petrus (1998) and 
Prasad (2008) are replaced by the high dose zinc groups with the longest durations of colds by 
Smith (1989) and Turner (2000a), and the order of pairing is shuffled, the estimate of “high dose 
vs low dose zinc lozenge” difference can fall to as low as 1.75 days, which is half of the difference 
(i.e. 3.43 days) reported by Das and Singh (2014), see p. 11. Thus, the reported estimate of “high 
dose vs low dose zinc lozenge” difference reported by Das and Singh (2014) is meaningless since 
it is based on the arbitrary pairing of arbitrarily selected zinc groups from 12 different studies.
Furthermore, in the set of 5 low dose zinc groups, the dose of zinc is not the only relevant issue. 
The lozenge preparations used in some studies would not be expected to release zinc effectively. 
Eby (2001) pointed out that the Turner (2000) lozenges contained palm kernel and cotton-seed oils, 
and at the high temperatures used in the manufacture of these lozenges those ingredients react with 
zinc ions to make insoluble compounds. The lozenge used by Douglas (1987) contained a high 
amount of tartaric acid, which binds zinc and therefore free zinc ions are not easily released from 
such lozenges (Eby 2004, p. 31). The 2 zinc groups reported by Turner (2000) and the 1 zinc group 
reported by Douglas (1987) cover 3 of the 5 “low dose zinc lozenge” studies. Thus, the lack of 
effect by zinc in these 3 studies (compared with their respective placebos) might be, at least partly, 
unrelated to the nominal zinc dosage per se, and could instead be caused by the poor solubility of 
zinc caused by the lozenge formulations. Thus, because of the problems with the lozenge 
formulations, these 3 studies are not suitable for an analysis of dose response effects of zinc 
administered as lozenges. Finally, the only trial that has been done with children (6 to 16 y) by 
Macknin (1998) falls to the low dose group. It is possible that the effect of zinc lozenges is different
in children compared with adults, so that the zinc dose cannot be considered as the only relevant 
issue in that study when compared with the Mossad (1996) study.
As noted on p. 4, the only trial that has administered different doses of zinc to randomized groups 
was reported by Turner (2000). However, the composition of the lozenges was not satisfactory for 
the reasons detailed above. Thus, although Turner (2000) is the only study that could provide 
relevant information of dose response of zinc effects from the clinical trial point of view, that study 
was limited by the lozenge formulations.
There is strong evidence that a high dose (>75 mg/day) zinc lozenges shorten the duration of colds, 
but so far there is no evidence that low dose (<75 mg/day) zinc lozenges shorten colds (Hemilä 
2011). That limit of 75 mg/day was introduced as a pragmatic cut off limit to visualize the 
systematic differences between the high and low dosage studies (Hemilä 2011). However, the 
published low dose studies may also be negative for reasons other than the actual zinc dose used, 
as pointed out above. For example, we do not know if, say, 50 mg/day of zinc as zinc acetate 
lozenges might substantially influence the duration of colds if an optimal formulation of lozenges 
is used.
For the reasons listed above from A) to E), the findings reported on the third row of the Table 
of the JAMA Synopsis are not valid. 
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A different selection of “high zinc” groups and a different pairing permutation 
of the “high zince” and “low zinc” groups can lead to a mean difference of common cold 
duration which is half of that reported by Das and Singh (2014)
 
In the JAMA Synopsis, Das and Singh (2014) reported that:
 
“The mean duration of the common cold was 4.47 days in high-dose users (≥75 mg/d) and 8.68 
days in low-dose users (<75 mg/d; mean difference, −3.43 [95% CI, −3.9 to −2.95])” (p. 1440).
 
The estimate of 3.43 days is based on the exclusion of 2 high dose zinc lozenge groups that reported
the longest colds (Smith 1989 and Turner 2000a) and on the pairing of high zinc vs. low zinc groups
in the order they were listed in Analysis 1.2, see pp. 6-9. 
 
 
 
There is no justification for the particular selection of the 5 uppermost high dose studies in Analysis
1.2.1 by Das and Singh (2014), nor for the specific pairing of the high zinc and low zinc studies by 
their order on the list. 
 
If the 2 high dose zinc groups with the shortest colds are replaced by the zinc groups of Smith 
(1989) and Turner (2000a), and the pairing is shuffled, a difference of 1.75 days is reached between 
the high zinc vs low zinc groups, see the meta-analysis below. In the pairing shown below, the order
of the “low zinc” studies is kept the same as in the meta-analysis on p. 8.
 
This difference of 1.75 days is half of the 3.43 day difference reported in the JAMA synopsis, 
see p. 3. However, this particular selection of high dose zinc lozenge studies and this pairing is no 
less applicable than the selection and pairing leading to the 3.43 day difference published by Das 
and Singh (2014), see p. 8 of this document.
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3. Calculating the effect of zinc syrup on the duration of colds
On the second row of the Table, the JAMA Synopsis by Das and Singh (2014) (see p. 3) 
reported that in 2 zinc syrup studies with 314 participants, the mean duration of colds was: 
5.1 days (SD 0.4) in the zinc groups, and 
5.9 days (SD 0.6) in the placebo groups. 
The difference in cold duration between the syrup and placebo groups was reported as: 
“−0.63 (−0.84 to −0.43)” days.
These findings are also repeated in the text section of the JAMA synopsis by Das and Singh (2014) :
“The mean duration was 5.1 days in the syrup group and 5.9 days in the placebo group 
(mean difference, −0.63 [95% CI, −0.84 to −0.43])” (p. 1440).
 
I searched for the data used in the Cochrane review by Singh and Das (2013) and figured out how 
to reproduce the calculations behind the figures published for the 2 zinc syrup studies.
The figures reported on zinc syrup studies in the JAMA Synopsis can be traced to Analysis 1.2.6 
in the Cochrane review by Singh and Das (2013, p. 52), see p. 15 for a copy of that analysis. 
Two studies by Kurugöl (2006a, 2007) have examined the effect of zinc syrup on common cold 
duration. The analysis of these studies is reproduced on the next page. The mean durations reported 
in the Table of the JAMA Synopsis by Das and Singh (2014) are given as unweighed means. 
Similarly, the SDs are not calculated from the study SDs (the correct way), but they are calculated 
from the study means (the point estimates; the incorrect way as explained on p. 9).
The effect of zinc syrup was −0.63 (−0.84 to −0.43) days according to the JAMA Synopsis 
by Das and Singh (2014). According to the Analysis 1.2.6 of the Cochrane review by Singh 
and Das (2013), the effect of zinc syrup was −0.65 (−0.92 to −0.39) days, see p. 15 of this 
document. The former value was calculated by the fixed effect model, whereas the latter was 
calculated using the random effects model, which explains the slight difference. 
The presentation of zinc syrup findings suffers from the problems described in D) and E) on p. 9.
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Calculation of the zinc syrup mean and SD reported by Das and Singh (2014) 
from the means reported in Analysis 1.2 of Cochrane review 
“Zinc for the common cold” by Singh and Das (2013)
The table below shows the means and SDs for the duration of colds in Singh and Das (2013).
See p. 15 for a copy of Analysis 1.2.6.
The bold numbers indicate the values reported in the JAMA Synopsis by Das and Singh (2014). 
 
 
 
Reproducing the analysis of the effect of zinc syrup on the duration of colds 
in the JAMA synopsis by Das and Singh (2014)
 Analysis 1.2.6 in Singh and Das (2013)
 Zinc as syrup Study No. ofparticipants
Duration of
colds (days)
Kurugöl (2006a) 97 4.7  
Kurugöl (2007) 60 5.5  
Total  157 
Mean (unweighed)  5.10 
SD (population)  0.400
 Placebo Study
Kurugöl (2006a) 97 5.3  
Kurugöl (2007) 60 6.5  
Total  157 
Mean (unweighed)  5.90 
SD (population)  0.600
Overall Total  314 
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4. Calculating the effect of zinc lozenges on the duration of colds
 
On the first row of the Table in the JAMA Synopsis (see p. 3), Das and Singh (2014) reported 
that in 12 studies with 1342 participants, the mean duration of colds was:
6.75 days (SD 2.36) in the zinc groups, and 
7.5 days (SD 4.03) in the placebo groups. 
The difference in cold duration between the syrup and placebo groups was reported as: 
“−1.04 (−2.02 to −0.05)” days.
The findings are also repeated in the text section:
“The mean duration of cold symptoms was 6.75 days in the lozenge group and 7.5 days 
in the placebo group (mean difference, −1.04 [95% CI, −2.02 to −0.05)” (p. 1440).
 
The findings reported on the first row of the Table published in the JAMA Synopsis originates 
from Analysis 1.2.5 in the Cochrane review by Singh and Das (2013, p. 52), see the next page.
Analysis 1.2.5 of the Cochrane review by Singh and Das (2013) has two serious errors, which were 
passed directly onto the JAMA Synopsis.
First, Analysis 1.2.5 wrongly states that the duration of colds was 4.4 days in the zinc group 
of the Petrus (1998) study, whereas Petrus (1998) actually reported that the duration was 3.8 days, 
see the next page. In 2011, I wrote a Feedback (2011) on the previous version of the Cochrane 
review by Singh and Das (2011), in which I pointed out that error of data extraction. Despite this, 
the wrong figure of 4.4 days remained in the updated Cochrane review by Singh and Das (2013), 
see p. 15. This leads to an incorrect mean duration of colds in the zinc groups reported in the JAMA
Synopsis (i.e. 6.75 days is not correct).
Second, Analysis 1.2.5 in Singh and Das (2013) counts the placebo-group of Turner (2000) 
3 times. This leads to 142 (= 2 * 71) phantom participants in the placebo column, see p. 15. 
The correct number of participants in the 12 lozenge studies is therefore not 1342 as stated in 
the Table of JAMA Synopsis (see p. 3), but it is 1200 participants. The multiple counting introduces
an error in the mean duration of colds in the placebo groups (i.e. 7.5 days is not correct) and also 
leads to misleading accuracy of the Turner (2000) comparisons. The problems of multiple counting 
of the same participants is briefly commented on in the Cochrane Handbook:
“A serious unit-of-analysis problem arises if the same group of participants is included twice 
in the same meta-analysis (for example, if ‘Dose 1 vs Placebo’ and ‘Dose 2 vs Placebo’ are 
both included in the same meta-analysis, with the same placebo patients in both 
comparisons)” (Higgins 2011, sec 9.3.9).
The two errors described above cause that the published unweighed mean values (6.75 and 7.5 
days) and the estimate of the effect of zinc lozenges (1.04 days) are all wrong. Furthermore, the 
approach of calculating the unweighed mean duration of colds in the zinc and placebo groups 
in the Table suffers from the problem D) described on p. 9.
The SD calculated from the means of the zinc groups (the incorrect way) is 2.37 which is very close
to the reported SD = 2.36, see p. 3. However for the placebo groups (see p. 3), the reported SD = 
4.03 is not calculated from the means of the placebo groups. The pooled SD (PV 2015) for the 
placebo groups is 4.20 which is quite close to the reported SD = 4.03 and it is thus possible that the 
placebo SD is calculated from the SD values of the studies (the correct way).
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Analyses 1.2.5 and 1.2.6 in the Cochrane review “zinc for the common cold” 
by Singh and Das (2013, p. 52)
At the foot of this page is a copy of the Table II of Petrus (1998)
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Calculation of the adverse events in the zinc lozenge studies by Das and Singh (2014)
The bold figures are those reported in the JAMA Synopsis by Das and Singh (2014). 
However, the reported mean rate of adverse events of 36.4% is based on counting 
the Turner (2000) placebo group data 3 times by Das and Singh (2014).
Counting the Turner (2000) placebo group just once (the correct way) leads 
to placebo group mean rate of adverse events of 48.4%, which is marked by yellow.
Reproducing the rate of adverse events caused by zinc lozenges 
in the JAMA synopsis by Das and Singh (2014)
 Analysis 2.12 of Singh and Das (2013)
Study No. ofparticipants
No. of any
adverse events
Proportion with
adverse events
 Zinc lozenges Macknin (1998) 123 106  86%
Mossad (1996) 49 44 90%
Turner (2000a) 68 11 16%
Turner (2000b) 68 9 13%
Turner (2000c) 72 14 19%
Weismann (1990) 61 21 34%
Total:  441 205  
Ratio of total events  
per total participants:  46.5%
 Placebo Macknin (1998) 124 99 80%
Mossad (1996) 50 31 62%
Turner (2000) 71 7 10%
  Second counting:  Turner (2000) 71 7 10%
  Third counting:  Turner (2000) 71 7 10%
Weismann (1990) 69 15 22%
Counting the Turner (2000)
placebo group 3 times
 (Das and Singh 2014):
Total:  456 166  
Ratio of total events  
per total participants:  36.4%
Counting the Turner (2000)
  placebo group only once
  (the correct way):
Total:  314 152  
Ratio of total events  
per total participants:    48.4%  
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5. Calculation of the rate of adverse events in the zinc lozenge studies 
 
In the text section of the JAMA Synopsis, Das and Singh (2014, p. 1440) report on the adverse 
events caused by zinc lozenges as follows:
“Zinc lozenges were associated with a higher incidence of adverse events compared with placebo
(46.5% for lozenges vs 36.4% for placebo; number needed to harm [NNH], 10).”
 
The percentages of adverse events are not reported in the Cochrane review by Singh and Das 
(2013). The data for the above percentages, however, can be traced to Analysis 2.12 of the Cochrane
review by Singh and Das (2013, p. 65), see the previous page for the data extracted from that 
analysis.
In the Cochrane review by Singh and Das (2013) there were 12 zinc lozenge studies, but the 
analysis of adverse events is based on just 6 studies. In the JAMA Synopsis, Das and Singh (2014) 
calculated the mean rate of adverse events as follows. All participants in the 6 studies were 
summed, and all adverse events in the 6 studies were summed. Thereafter, the total sum of adverse 
events were divided by the total number of participants to obtain the mean rate of adverse events, 
which was published by Das and Singh (2014). A similar calculation was done for both the zinc and
the placebo groups. This calculation is shown on the previous page, with bold type indicating the 
figures published by Das and Singh (2014).
In the 3 zinc lozenge groups reported by Turner (2000), the rate of adverse events varied from 
13% to 19%, whereas in the Macknin (1998) study the rate was as high as 86%. The rate of adverse 
events in the placebo groups varied similarly from 10% in the Turner (2000) study to 80% in 
the Macknin (1998) study. 
The analysis of adverse events reported in the JAMA Synopsis by Das and Singh (2014) has 
statistical problems and problems related to the compositions of lozenges.
First, here again Das and Singh (2014) counted the placebo group of Turner (2000) three times. 
If the triple counting is corrected by counting just once, the total number of placebo participants 
in the remaining 4 studies is 314, and they had 152 adverse events, which gives mean rate of 
adverse events in the placebo groups of 48.4%, see the previous page. This rate is 12 percentage 
points higher than the mean rate (36.4%) calculated for placebo groups in the JAMA Synopsis, 
see above. The corrected placebo rate is even slightly higher than the rate of 46.5% that was 
calculated for the zinc groups, see above. Thus, the 10% higher rate of adverse events in the zinc 
lozenge groups, reported by Das and Singh (2014), is a statistical artefact caused by the triple 
counting of the single placebo group of Turner (2000). Consequently, the NNH reported by Das 
and Singh (2014) is also incorrect.
Second, when there is such a dramatic variation in the adverse events from 10% to 80% in the 
placebo groups, and a similar variation for the zinc groups, it seems obvious that there cannot be 
a uniform rate of adverse events that is valid for all conditions. For example, comparison of the 
rates of the adverse events in the placebo groups reported by the Turner (2000) study (10%; 7/71) 
and the Macknin (1998) study (80%; 99/124) gives P = 10-15 difference as calculated by using the 
Fisher exact test. Thus, random variation is not a credible explanation for such huge differences 
in rates of adverse events, and it is not reasonable to combine such inconsistent rates.
Some probable factors for the great variations in the rate of adverse events are the differences in 
definitions of adverse events, and the differences in the recording and reporting practices of adverse
events between studies. Furthermore, even if an identical definition for adverse events was used, 
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it is highly plausible that some population groups report adverse events more sensitively than other 
population groups and this depends on gender, age, education, etc. Therefore, statistically the most 
reasonable approach is first to calculate the difference between zinc and placebo groups for each 
study, and thereafter pool the estimates by standard meta-analysis methods. Such an approach 
adjusts for the baseline variations in the rates of adverse events. The calculation method used by 
Das and Singh (2014) does not adjust for the baseline variations.
Furthermore, given that 3 studies on high dose zinc lozenges (Petrus 1998, Prasad 2000, Prasad 
2008) had an average 42% reduction in the duration of common cold (Hemilä 2011, 2015), the most
relevant question is: Do high dose zinc acetate lozenges cause adverse effects? The analysis by Das 
and Singh (2014) did not include any one of these 3 high dose zinc acetate lozenge studies. 
Macknin (1998), Mossad (1996), Turner (2000a) and Weismann (1990) used lozenges made of zinc 
gluconate, see p. 16. Some types of zinc gluconate lozenges end up tasting bad after storage, but 
zinc acetate does not have such a problem, see Eby (2004, p. 34-35):
“Taste problems and oral irritation using zinc gluconate (ZG) caused most if not all of 
the problems found in commercializing zinc lozenges for colds. To reduce or eliminate 
the ZG/dextrose reaction and oral irritation, some manufacturers either used low amounts 
of ZG or added strong zinc binding agents, which reduced or eliminated efficacy. Although 
pure ZG is bland and chalky in taste, it reacts with dextrose and related carbohydrates 
(excluding fructose) upon aging of lozenge compositions to produce noisome bitterness and 
compliance-related inefficacy. ZG releases large amounts of neutrally charged hydroxide 
species likely to cross cell membranes and causes oral irritation. Bitterness occurs in all ZG 
lozenges except those that either do not contain carbohydrates (excluding fructose), or that 
contain strong extramolar zinc binding agents, which results in something other than ZG. For 
these reasons, ZG is no longer believed suitable for use in zinc lozenges for treating colds.
On the other hand, zinc acetate allows the production of pleasant tasting, flavor stable 
lozenges releasing large amounts of iZn [free zinc ions] either in hard candies or compressed 
tablets without flavor or stability issues. The mouth-feel produced is sufficiently like the 
mouth-feel of tea (slight astringency) to allow using tannic acid without added bitter agents 
as a placebo in clinical trials.”
None of the high dose zinc acetate lozenge trials (Petrus 1998, Prasad 2000, Prasad 2008) reported 
bad taste to be a problem and there was no substantial difference between the zinc and placebo 
groups in the recorded adverse effects, and only a few drop-outs occurred. For example, the most 
recent of these studies, Prasad (2008) reported in Table 3 of their publication that a sour taste was 
more common in the zinc group (7/25 vs. 2/25, though P = 0.13 for the difference) whereas nausea 
(3 vs 1) or constipation (2 vs 1) and diarrhea (1 vs 1) did not differ considerably between groups. 
Thus, the high dose zinc acetate lozenge did not seem to cause harm, either as bad taste or within 
the GI region. Furthermore, when a common cold patient experiences acute adverse effects such as 
bad taste, the particular patient can simply stop taking the zinc acetate lozenges.
Given that the strongest evidence of benefit is found for high dose zinc acetate lozenges, the 
possible bad taste of zinc gluconate lozenges is not a relevant issue. In particular, the bad taste of 
some zinc gluconate lozenges cannot be extrapolated to infer bad taste of the zinc acetate lozenges. 
Thus, the 10 percentage point difference in adverse events between zinc lozenge and placebo groups
that was calculated by Das and Singh (2014) can be explained by the triple counting of the Turner 
(2000) placebo group. Furthermore, summing all adverse events and dividing by all participants 
as was done by Das and Singh (2014) is statistically unsound. Finally, even if the analysis of 
adverse events had no such statistical problems, it would still be uninformative about the adverse 
events of high dose zinc acetate lozenges, for which there is compelling evidence of effectiveness 
(Hemilä 2011, 2015).
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